Selectimmune Pharma AB (publ) reported earnings results for the second quarter and six months ended December 31, 2022. For the second quarter, the company reported net loss was SEK 1.34 million compared to SEK 4.5 million a year ago. Basic loss per share from continuing operations was SEK 0.0766 compared to SEK 0.2576 a year ago.
For the six months, net loss was SEK 2.75 million compared to SEK 7.63 million a year ago. Basic loss per share from continuing operations was SEK 0.1575 compared to SEK 0.437 a year ago.